Life Sciences Regulation And Legislation To Watch In 2014
Law360, New York (January 1, 2014, 10:08 AM EST) -- Recent directives by the U.S. Food and Drug Administration, federal courts and Congress will drive some big regulatory shifts in the life sciences field in 2014, with attorneys watching especially the implementation of the newly passed Drug Quality and Security Act and the regulation of direct-to-consumer marketing.
Life sciences attorneys are also eagerly expecting the biosimilars guidance the FDA promised in October, which could pave the way for the first-ever biosimilar product approval since legislation on the novel treatments was approved five years ago. Pharmaceutical firms are also awaiting the FDA's reaction to a major Second Circuit ruling in late 2012...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!